Volume 30, Number 3—March 2024
Research
Monitoring and Characteristics of Mpox Contacts, Virginia, USA, May–November 2022
Eleanor N. Field
, Elizabeth McCarty, Dawn Saady, and Brandy Darby
, Elizabeth McCarty, Dawn Saady, and Brandy Darby
Table 3
Vaccine uptake and postexposure timeliness in mpox contact tracing and symptom monitoring cohort, Virginia, USA, May 1–November 1, 2022*
| Characteristic | Value |
|---|---|
| All persons | 991 |
| Received >1 dose | 333 (33.6) |
| Before exposure | 27 (8.4) |
| After exposure | 295 (91.6) |
| Unable to determine | 10 |
| Received 2 doses |
212 (63.7) |
| Persons vaccinated after exposure | 295 |
| Median time from exposure to first dose, d | 8 (range 4–12) |
| No. receiving 1st dose within <4 days of exposure | 82 (27.8) |
| No. receiving 1st dose within <14 days of exposure | 252 (85.4) |
*Values are no (%) except as indicated. Calculated percentages exclude missing values.
Page created: January 18, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.